Relationship between ovarian cancer stem cells, epithelial mesenchymal transition and tumour recurrence

Abstract

Investigating the biological processes that occur to enable recurrence and the development of chemoresistance in ovarian cancer is critical to the research and development of improved treatment options for patients. The lethality of ovarian cancer is largely attributed to the recurrence of disease with acquired chemoresistance. Cancer stem cells are likely to be critical in ovarian cancer progression, contributing to tumour malignancy, metastasis and recurrence by persisting in the body despite treatment with anti-cancer drugs. Moreover, cancer stem cells are capable of mediating epithelial-to-mesenchymal transition traits and secrete extracellular vesicles to acquire therapy resistance and disease dissemination. These attributes merit in depth research to provide insight into the biological role of ovarian cancer stem cells in disease progression and chemotherapy response, leading to the development of improved biomarkers and innovative therapeutic approaches.

Keywords

Ovarian cancer / stem cells / chemoresistance / platinum resistance / recurrence / epithelial-to-mesenchymal transition / extracellular vesicles

References

[1] Albini A,Gallo C,Noonan DM.Cancer stem cells and the tumor microenvironment: interplay in tumor heterogeneity..Connect Tissue Res2015;56:414-25 PMCID:PMC4673538

[2] Ushijima K.Treatment for recurrent ovarian cancer-at first relapse..J Oncol2010;2010:497429 PMCID:PMC2801501

[3] Pieterse Z,Singomat T,Madjid BD.Ovarian cancer stem cells and their role in drug resistance..Int J Biochem Cell Biol2019;106:117-26

[4] Berek JS,Friedlander M.Cancer of the ovary, fallopian tube, and peritoneum..Int J Gynecol Obstet2015;131:S111-22

[5] Kim A,Naka T.Therapeutic strategies in epithelial ovarian cancer..J Exp Clin Cancer Res2012;31:14 PMCID:PMC3309949

[6] Yu Y,Phillip Jude M,Pinto Sneha M.Inhibition of spleen tyrosine kinase potentiates paclitaxel-induced cytotoxicity in ovarian cancer cells by stabilizing microtubules..Cancer Cell2015;28:82-96 PMCID:PMC5257279

[7] Sebastian V,Robert CB,Jonathan SB.Rethinking ovarian cancer: recommendations for improving outcomes..NatRev Cancer2011;11:719 PMCID:PMC3380637

[8] Markman M,Hakes T,Hoskins W.Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin..J Clin Oncol1991;9:389-93

[9] Luvero D,Ledermann JA.Treatment options in recurrent ovarian cancer: latest evidence and clinical potential..Ther Adv Med Oncol2014;6:229-39 PMCID:PMC4206613

[10] Stuart GCE,Bacon M,Friedlander M.2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference..Int J Gynecol Cancer2011;21:750-5

[11] Rahman M,Deleyrolle L,Reynolds BA.The cancer stem cell hypothesis: failures and pitfalls..Neurosurgery2011;68:531-45discussion 545

[12] Abubaker K,Luwor R,Zhu H.Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden..Molecular Cancer2013;12:24 PMCID:PMC3668985

[13] Landen CN,Katre AA,Nick AM.Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer..Mol Cancer Ther2010;9:3186-99 PMCID:PMC3005138

[14] Latifi A,Castrechini N,Liongue C.Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile..J Cell Biochem2011;112:2850-64

[15] Tan BT,Ailles LE.The cancer stem cell hypothesis: a work in progress..Lab Invest2006;86:1203-7

[16] Choi YL,Shin YK,Lee SJ.Cytoplasmic CD24 expression in advanced ovarian serous borderline tumors..Gynecol Oncol2005;97:379-86

[17] Nakamura K,Tanabe A,Hayashi M.CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways..Oncol Rep2017;37:3189-200 PMCID:PMC5442399

[18] Meng E,Sullivan P,Finan MA.CD44+/CD24- ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival..Clin Exp Metastasis2012;29:939-48

[19] Taddei A,Amunni G,Taddei GL.c-KIT expression and correlation with chemotherapy resistance in ovarian carcinoma: an immunocytochemical study..Ann Oncol2004;15:594-7

[20] Abubaker K,Escalona R,Quinn MA.Targeted disruption of the JAK2/STAT3 pathway in combination with systemic administration of paclitaxel inhibits the priming of ovarian cancer stem cells leading to a reduced tumor burden..Front Oncol2014;4:75 PMCID:PMC3988380

[21] Baba T,Matsumura N,Kondoh E.Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells..Oncogene2008;28:209

[22] Kalluri R.The basics of epithelial-mesenchymal transition..J Clin Invest2009;119:1420-8 PMCID:PMC2689101

[23] Mani SA,Liao MJ,Ayyanan A.The Epithelial-mesenchymal transition generates cells with properties of stem cells..Cell2008;133:704-15 PMCID:PMC2728032

[24] Lamouille S,Derynck R.Molecular mechanisms of epithelial-mesenchymal transition..Nat Rev Molecular Cell Biol2014;15:178-96 PMCID:PMC4240281

[25] Thiery JP,Huang RYJ.Epithelial-mesenchymal transitions in development and disease..Cell2009;139:871-90

[26] Acloque H,Fishwick K,Nieto MA.Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease..J Clin Invest2009;119:1438-49 PMCID:PMC2689100

[27] Chaffer CL,Lim E.EMT, cell plasticity and metastasis..Cancer Metastasis Rev2016;35:645-54

[28] Takai M,Kawaguchi H,Fujiwara S.The EMT (epithelial-mesenchymal-transition)-related protein expression indicates the metastatic status and prognosis in patients with ovarian cancer..J Ovarian Res2014;7:76 PMCID:PMC4127950

[29] Davidson B,Hellesylt E,Huang RY.The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions..Human Pathology2015;46:1-8

[30] Zhu X,Yin X,Xie C.miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin..Oncogene2016;35:323-32

[31] Haslehurst AM,Dharsee M,Evans K.EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer..BMC Cancer2012;12:91 PMCID:PMC3342883

[32] Chowanadisai W,Miller DH,Hamilton JW.Cisplatin resistant spheroids model clinically relevant survival mechanisms in ovarian tumors..PLoS One2016;11:e0151089 PMCID:PMC4795743

[33] Brabletz T,Spaderna S,Kirchner T.Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression..Nat Rev Cancer2005;5:744-9

[34] Lupia M,Bertalot G,Sachsenmeier KF.CD73 regulates stemness and epithelial-mesenchymal transition in ovarian cancer-initiating cells..Stem Cell Reports2018;10:1412-25 PMCID:PMC5998305

[35] Allard D,Gaudreau PO,Stagg J.CD73-adenosine: a next-generation target in immuno-oncology..Immunotherapy2016;8:145-63

[36] Wu C.Side population cells in human cancers..Cancer Lett2008;268:1-9

[37] Wu C,Utomo V,Whetstone H.Side population cells isolated from mesenchymal neoplasms have tumor initiating potential..Cancer Res2007;67:8216-22

[38] Marchini S,Clivio L,Porcu L.Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer..Eur J Cancer2013;49:520-30

[39] Pouyafar A,Abdolalizadeh J,Talebi M.Modulation of lipolysis and glycolysis pathways in cancer stem cells changed multipotentiality and differentiation capacity toward endothelial lineage..Cell Biosci2019;9:30 PMCID:PMC6437852

[40] Liu A,Liu S.Pluripotency transcription factors and cancer stem cells: small genes make a big difference..Chinese journal of cancer2013;32:483-7 PMCID:PMC3845564

[41] Mitra T,Mukherjee P,Chatterji U.Stemness and chemoresistance are imparted to the OC cells through TGFβ1 driven EMT..J Cell Biochem2018;119:5775-87

[42] Fletcher JI,Henderson MJ.ABC transporters in cancer: more than just drug efflux pumps..Nat Rev Cancer2010;10:147

[43] Jiang H,Liu Y,Ma X.Transformation of epithelial ovarian cancer stemlike cells into mesenchymal lineage via EMT results in cellular heterogeneity and supports tumor engraftment..Molecular medicine (Cambridge, Mass)2012;18:1197-208 PMCID:PMC3510297

[44] Parida S,Maji RK.Elucidating the gene regulatory networks modulating cancer stem cells and non-stem cancer cells in high grade serous ovarian cancer..Genomics2019;111:103-13

[45] Liu S,Cai B,Yang L.NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer..Tumor Biology2016;37:9671-80

[46] Qin S,Cao X,Huang X.NANOG regulates epithelial-mesenchymal transition and chemoresistance in ovarian cancer..Biosci Rep2017;37:BSR20160247 PMCID:PMC5223747

[47] Akhter MZ,Kumar V,Equbal Z.Aggressive serous epithelial ovarian cancer is potentially propagated by EpCAM(+)CD45(+) phenotype..Oncogene2018;37:2089-103

[48] Li Y,Zhu J,Jiang H.High ALDH activity defines ovarian cancer stem-like cells with enhanced invasiveness and EMT progress which are responsible for tumor invasion..Biochem Biophys Res Commun2018;495:1081-8

[49] Sun YZ,Jiang ZS,Wang SM.Extracellular vesicles: a new perspective in tumor therapy..BioMed Res Int2018;2018:2687954 PMCID:PMC5937590

[50] Alharbi M,Elfeky O,Lai A.The potential role of miRNAs and exosomes in chemotherapy in ovarian cancer.2018;25:R663

[51] Safaei R,Cheng TC,Otani S.Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells..Mol Cancer Ther2005;4:1595-604

[52] Crow J,Banskota S,Schmitt S.Exosomes as mediators of platinum resistance in ovarian cancer..Oncotarget2017;8:11917-36 PMCID:PMC5355315

[53] Wang Y,Li Y,Wang X.Exosomes/microvesicles from induced pluripotent stem cells deliver cardioprotective miRNAs and prevent cardiomyocyte apoptosis in the ischemic myocardium..Int J Cardiol2015;192:61-9 PMCID:PMC4469495

[54] Liao TT.Revisiting epithelial-mesenchymal transition in cancer metastasis: the connection between epithelial plasticity and stemness..Mol Oncol2017;11:792-804 PMCID:PMC5496497

[55] Cha SY,Hwang S,An HJ.Clinical impact of microRNAs associated with cancer stem cells as a prognostic factor in ovarian carcinoma..J Cancer2017;8:3538-47 PMCID:PMC5687169

[56] Srivastava AK,Cui T,Cai S.Inhibition of miR-328-3p impairs cancer stem cell function and prevents metastasis in ovarian cancer..Cancer Res2019;79:2314-26 PMCID:PMC6777340

[57] Tung SL,Hsu FC,Jang TH.miRNA-34c-5p inhibits amphiregulin-induced ovarian cancer stemness and drug resistance via downregulation of the AREG-EGFR-ERK pathway..Oncogenesis2017;6:e326 PMCID:PMC5525454

[58] Liu J,Liu H,Gao X.Expression of microRNA-30a-5p in drug-resistant and drug-sensitive ovarian cancer cell lines..Oncol Lett2016;12:2065-70 PMCID:PMC4998657